Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We've see the last dip for this stock, time to see a new HOD. $RGBP
2,000,000 MINUS 1,850,000 is 250,000...... I'm not all the great at math but come on man
Tomorrow it will be past 2 Mil, if you're stuck on $150,000 short of 2 mil then you argue to hear yourself,..guess what man, I'll buy more and ride this, you can wait until ONPH hits $40 PPS to make a decision LMFAO.
Those 50k shares are 2 mil dollars now (ONPH $37 PPS) and they will be worth much more, the royalties paid for 15 years straight, the patents alone are worth millions and the buyout that its coming soon, big players will try to take this company over, that is where the money lies, ...who's looking to Takeover RGBP, Pfizer, Moderna, Shkreli, Gates, ONPH itself ? Think my friend, this is just the beginning,
Risk Vs Reward is huge here....and honestly speaking...there's no risk.
If guppies like us don't sleep, Sharks do not either.
I can tell you one thing for sure with or without Financial Insider...this stock is not worth only 6 cents.
Insider financial predicted $8 PPS
Regen BioPharma About To Become A Major Pharma Player
https://insiderfinancial.com/regen-biopharma-about-to-become-a-major-pharma-player/181241/
ByAlex CarlsonWritten Post on April 10 2021
The entire OTC Market is talking about just one stock this week and that’s Regen BioPharma (OTCMKTS: RGBP). The stock rocketed 957% in just two days after signing a deal with Oncology Pharma (OTCMKTS: ONPH) for the treatment of pancreatic and colon cancer.
Its preferred shares also took off.
We really like this move in Regen BioPharma because this could be the spark that gets investors excited about OTC stocks again. Last year, it was Tesoro Enterprises and its merger with HUMBL Inc (OTCMKTS: HMBL) that set the OTC Markets on fire as it became the biggest runner of 2020.
What we like about Regen BioPharma is that it is at the same price where we recommended HMBL to our readers and subscribers, which you can read here. HMBL would go on to run to almost $8 from just $.027 a share.
We think RGBP has just as much potential. In this article, we take a look at the recent 8-Ks from Regen BioPharma and why we believe RGBP stock can keep running.
REGEN BIOPHARMA
First up, here’s a little background info for those not familiar with the company. Regen BioPharma is a publicly-traded biotechnology company focused on the immunology and immunotherapy space.
The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.
The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
MESSENGER RNA – KNOWN AS MRNA
Regen BioPharma signed a license agreement with Oncology Pharma for intellectual property pertaining to mRNA (messenger RNA) to be used in developing a therapy for treating pancreatic cancer.
The License IP consists of antigen-specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments the likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
mRNA is important because it is the foundation of the Moderna and Pfizer COVID-19 vaccines.
Messenger RNA – known as mRNA – are genetic instructions for our cells. mRNA serves as a code to make proteins. Proteins are needed for cellular functions inside our bodies, including growth, energy production, and defense against illnesses.
mRNA technology is a strand of mRNA created in a lab that prompts the recipient’s cells to create protein fragments that are based on the “non-self” DNA characteristics of the vaccine’s target. When recognized, the protein fragments trigger a response from the patient’s immune system.
As with the COVID-19 vaccines, the mRNA instructs the patient’s cells to produce protein fragments based off a tumor’s genetic mutations identified during testing. The immune system then searches for other cells with the mutated proteins and clears out any remaining circulating tumor cells.
ONCOLOGY PHARMA DEALS
Regen BioPharma signed two deals with Oncology Pharma. One is between Oncology and Regen for treating pancreatic cancer. The second is between Regen’s wholly-owned subsidiary KCL Therapeutics, Inc and Oncology for the treatment of colon cancer.
As consideration to Regen for the rights and license granted pursuant to the Agreement Oncology Pharma shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment
As consideration to KCL Therapeutics for the rights and license granted pursuant to the Agreement Oncology Pharma shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment
The 50,000 shares of Oncology Pharma are currently worth $1,700,000.
THE FIRST OF MORE TO COME FROM REGEN BIOPHARMA
What we really like about the deals with Oncology Pharma is that Regen BioPharma is sitting on a very valuable patent portfolio. It was just a matter of time before they started monetizing it. Just doing a Google patent search yields 23 results.
These deals further validate the premise that while there has been no news from the company in almost 2 years, Regen BioPharma and its CEO David Koos have been hard at work for shareholders.
UPDATING ITS FILINGS
OTC stocks that have the STOP sign due to not filing financials can be monster runners as they work to become current. Regen BioPharma filed an 8-K that they intend to complete their financials. Once the company files for 2019 and 2020, the STOP sign will be removed. This will allow more brokers to list RGBP and RGBPP for their customers to trade. This is why some folks at Fidelity for instance can’t purchase shares.
RGBP VS RGBPP
You can play Regen BioPharma by owning RGBP or RGBPP. The big difference is the share structure.
BOTTOM LINE
As we keep saying, there are always opportunities in the markets and it’s our job to find winning OTC stocks. Huge gains can be made in such a short amount of time.
If you like RGBP or RGBPP, our best advice is to be patient and throw bids in below the market. Buying dips and selling rips as swing trades remains the best strategy in these markets.
We believe that the 957% run in RGBP is just what the OTC Markets needed. When investors start hearing about 10-baggers they go where the fast money can be made. We saw that last year with TSNP/HMBL and how that hot stock fueled an OTC boom like we had never seen before in our 30 years of trading. There was a new 1000% runner every week.
This is why it’s important to look for OTC stocks that have yet to run. There are plenty of opportunities out there and we look at hundreds of OTC stocks to buy each week trying to find the best alerts for our subscribers.
Remember, all it takes is one or two to become a winner and you’ve crushed the market indices for the year.
As always, good luck to all (except the shorts)!
Read the deal again, ONPH paid in cash, stocks(which is much higher in value as of today) and royalties from profits 15% FOR THE NEXT 15 YEARS.
https://www.otcmarkets.com/filing/html?id=14860710&guid=sA3pUqWqs_6eSMh
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
As consideration to Regen for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.2 and incorporated in this Item 1.01 by reference.
LMFAO,keep dreaming, I've been trading for 20+ years, I can tell you that between me and my group we have $100,000 lined up in the morning to buy up the fear.
Friday the stock closed at 0275 and it opened at 0375, today it closed at 06, tomorrow it will open at 067 and it will never look back. $RGBP
But then again...you go ahead and wait at 03. LMFAO.
Cure for cancer and new Covid 19 vaccine, 'nuff said, if ONPH believes in this company and it's trading above $37...then so will I...ONPH will soon buy the whole company just to get their shares back and own the patents fair and square, ONPH has to pay Regen BioPharma for 15 years straight profits, the workers at RGBP can just go home and get paid for the next 15 years and I'm pretty sure they are smart enough to buy some shares of their own...go ahead sell your shares to me...I dare you.
Hell the company can just close their doors and still get paid, what makes them profit now is only their patents, ONPH pretty much works for us the shareholders.
Talk about not seeing the forest because is blocked by trees....lol
Peeps that bought at 6,7 and 8 cents will never let this go to 3 cents again, that price is long gone, see you at 10 cents tomorrow...we open at 0.067 $RGBP
P.S. People thought they could see 3 cents today and their ask became dead money in the box all day, sure as hell they won't see it tomorrow, we're at 116% from that already.
I feel bad for some of you that lost their shares, but congrats to longs, we'll take it from here to new highs $RGBP.
I put an order to buy wood pallets to stack all this money. $RGBP...so the next hot pick is WoodPallets.com LMFAO
Welcome to the club, best party in town $RGBP.
My account looks so sexy I won't dare look at it without putting on my suit and tie, LMFAO $RGBP Baby...all the way...Diamond Hands here.
I called on everybody I know and love dear to buy $RGBP, I would recommend this stock with confidence, millionaires are on their way to scoop shares...just so you know.
This past weekend was the longest weekend of my life, I couldn't wait for Monday, and boy... was it what I expected $RGBP.
In the OTC, all you need is one good stock to make it, $RGBP is that stock fellas, hold on and retire early.
I dare you flip this bad boy and you're out. $RGBP
LMFAO
Anyone know of a good song to play for the shorts, I feel bad for them. $RGBP.
$RGBP will have a forward split soon so it can protect itself from Takeovers, which right now is a high risk for the company as it became a target for acquisition by the big players in Pharma....and that's where preferred does not benefit.
You'll lose your shares shortly...tomorrow we open at 6 cents. $RGBP
Higher highs, and higher lows, stair stepping to the moon, $RGBP
$RGBP is going to break a nickel today.
$RGBP straight to Heaven !!!
Then we go higher.
You haven't posted because you just opened this account today.
You won't see under 03 anymore, that bus left a long time ago, my Etrade account shows 03 cents already even though it closed 0.0275.
Everyone here and the whole world can agree that the current Covid 19 vaccine is flawed and it has to many side effects, the world needs a vaccine that was not constructed to merely beat a deadline or for thirst of profit, and that's where Regen BioPharma will shine,..the turtle wins the race.
I sure hope so, but nobody can predict the human emotion in these markets....and I never bet on the human strength, I bet on their weakness.
I never said I'm selling my current position, I said I'm buying more when it dips, there's always a few that don't see the bigger picture and will take profits, thank God for dips so I can accumulate more. I see 05 on opening and many premarket trades, the shorts will suffer the most and I'm looking forward to it.
It will open at 0.05 on Monday...followed with a dip to 0.037 and then it's when I'll buy more shares.
ONPH will go higher therefore the shares granted to $RGBP will be worth way more.
Stocks like HEMP and CBBT have gone there in a flash and they we're worthless, so $RGBP is the best contender to do so.
It's news like this that makes REGEN BioPharma the new candidate for a new vaccine.
https://www.forbes.com/sites/williamhaseltine/2021/04/11/the-pfizerbiontech-covid-19-vaccine-is-less-effective-against-the-south-african-and-uk-variants-than-against-the-original-virus-according-to-a-new-real-world-study-from-israel/?sh=63171c4c5888&utm_source=ForbesMainFacebook&utm_medium=social&utm_campaign=socialflowForbesMainFB&fbclid=IwAR36OpTGTjbtfUz2ATcNC0tBd4s557Hq5MpAxRUfn5gATgw_4CHhmWFhxFk
The Pfizer/BioNTech Covid-19 Vaccine Is Less Effective Against The South African And UK Variants Than Against The Original Virus, According To A New “real-World” Study From Israel
I'm not pushing for preferred shares because in an even of an attempt to buyout the float, the company will forward split as Tesla, ClearWire and many others did to make it harder to do so by increasing the Market Cap, therefore Common share holders will find themselves with twice the riches in their accounts overnight.
They do... on conversion, the thing is in the case of a Takeover the only thing the company can do to prevent that from happening (or at least make it harder) is a forward split as Clearwire did when Sprint was buying up the float quietly directly from shareholders.
https://www.investopedia.com/terms/p/preferredstock.asp
Preferred Stock
By AKHILESH GANTI Reviewed by GORDON SCOTT Updated Mar 31, 2021
What Is a Preferred Stock?
The term "stock" refers to ownership or equity in a firm. There are two types of equity—common stock and preferred stock. Preferred stockholders have a higher claim to dividends or asset distribution than common stockholders.1? The details of each preferred stock depend on the issue.
KEY TAKEAWAYS
Preferred stockholders have a higher claim on distributions (e.g. dividends) than common stockholders.1?
Preferred stockholders usually have no or limited, voting rights in corporate governance.1?
In the event of a liquidation, preferred stockholders claim on assets is greater than common stockholders but less than bondholders.2?
Preferred stock has characteristics of both bonds and common stock which enhances its appeal to certain investors.
1:17
What Is The Difference Between Preferred Stock And Common Stock?
Understanding Preferred Stock
Preferred shareholders have priority over common stockholders when it comes to dividends, which generally yield more than common stock and can be paid monthly or quarterly.1? These dividends can be fixed or set in terms of a benchmark interest rate like the London InterBank Offered Rate (LIBOR)?, and are often quoted as a percentage in the issuing description.
Adjustable-rate shares specify certain factors that influence the dividend yield, and participating shares can pay additional dividends that are reckoned in terms of common stock dividends or the company's profits. The decision to pay the dividend is at the discretion of a company's board of directors.
Unlike common stockholders, preferred stockholders have limited rights which usually does not include voting.1? Preferred stock combines features of debt, in that it pays fixed dividends, and equity, in that it has the potential to appreciate in price. This appeals to investors seeking stability in potential future cash flows.
Companies in Distress
If a company is struggling and has to suspend its dividend, preferred shareholders may have the right to receive payment in arrears before the dividend can be resumed for common shareholders.1? Shares that have this arrangement are known as cumulative. If a company has multiple simultaneous issues of preferred stock, these may in turn be ranked in terms of priority. The highest ranking is called prior, followed by first preference, second preference, etc.
Preferred shareholders have a prior claim on a company's assets if it is liquidated, though they remain subordinate to bondholders. Preferred shares are equity, but in many ways, they are hybrid assets that lie between stock and bonds. They offer more predictable income than common stock and are rated by the major credit rating agencies. Unlike with bondholders, failing to pay a dividend to preferred shareholders does not mean a company is in default. Because preferred shareholders do not enjoy the same guarantees as creditors, the ratings on preferred shares are generally lower than the same issuer's bonds, with the yields being accordingly higher.2?
Voting Rights, Calling and Convertibility
Preferred shares usually do not carry voting rights, although under some agreements these rights may revert to shareholders that have not received their dividend.1? Preferred shares have less potential to appreciate in price than common stock, and they usually trade within a few dollars of their issue price, most commonly $25. Whether they trade at a discount or premium to the issue price depends on the company's credit-worthiness and the specifics of the issue: for example, whether the shares are cumulative, their priority relative to other issues, and whether they are callable.2?
If shares are callable, the issuer can purchase them back at par value after a set date. If interest rates fall, for example, and the dividend yield does not have to be as high to be attractive, the company may call its shares and issue another series with a lower yield. Shares can continue to trade past their call date if the company does not exercise this option.2?
Some preferred stock is convertible, meaning it can be exchanged for a given number of common shares under certain circumstances.2? The board of directors might vote to convert the stock, the investor might have the option to convert, or the stock might have a specified date at which it automatically converts. Whether this is advantageous to the investor depends on the market price of the common stock.
Typical Buyers of Preferred Stock
Preferred stock comes in a wide variety of forms and is generally purchased through online stockbrokers by individual investors. The features described above are only the more common examples, and these are frequently combined in a number of ways. A company can issue preferred shares under almost any set of terms, assuming they don't fall foul of laws or regulations. Most preferred issues have no maturity dates or very distant ones.2
Institutions are usually the most common purchasers of preferred stock. This is due to certain tax advantages that are available to them which are not to individual investors.3 Because these institutions buy in bulk, preferred issues are a relatively simple way to raise large amounts of capital. Private or pre-public companies issue preferred stock for this reason.
Preferred stock issuers tend to group near the upper and lower limits of the credit-worthiness spectrum. Some issue preferred shares because regulations prohibit them from taking on any more debt, or because they risk being downgraded. While preferred stock is technically equity, it is similar in many ways to a bond issue; One type, known as trust preferred stock, can act as debt from a tax perspective and common stock on the balance sheet.4 On the other hand, several established names like General Electric, Bank of America and Georgia Power issue preferred stock to finance projects.567
Frequently Asked Questions
What is a preferred stock?
A preferred stock is a class of stock that is granted certain rights that differ from common stock. Namely, preferred stock often possess higher dividend payments, and a higher claim to assets in the event of liquidation. In addition, preferred stock have a callable feature, which means that the issuer has the right to redeem the shares at a predetermined price and date as indicated in the prospectus. In many ways, preferred stock shares similar characteristics to bonds, and because of this are sometimes referred to as hybrid securities.
What is the difference between a preferred stock and a common stock?
While preferred stock and common stock are both equity instruments, they share important distinctions. First, preferreds receive a fixed dividend as dividend obligations to preferred shareholders must be satisfied first. Common stockholders on the other hand, may not always receive a dividend. Secondly, preferreds typically do not share in the price appreciation (or depreciation) to the same degree as common stock. Lastly, preferred typically have no voting rights, whereas common stockholders do.
What is an example of a preferred stock?
Consider a company is issuing a 7% preferred stock at a $1,000 par value. In turn, the investor would receive a $70 annual dividend, or $17.50 quarterly. Typically, this preferred stock will trade around its par value, behaving more similarly to a bond. Investors who are looking to generate income may choose to invest in this security. The most common sector that issues preferred stock is the financial sector, where preferred stock may be issued as a means to raise capital.
We'll see a half of dollar next week.
Common shares are the "preferred" now, once the company becomes profitable The Preferred will be the "Preferred"...catch my drift ?
Preferred shares are protected from R/S and they have higher voting power also they will become the main target for a hostile takeover in the coming months.
This company has become a good contender for a Buyout by the major players like Pfizer and Moderna.
ONPH will be buying $RGBP shares on the open market soon.....Dollar here I come
As of now Regen BioPharma is a target for a major buyout or take over by a major Pharmaceutical player, where's Martin when you need him, "Free Shkreli " LMFAO